AMGN · Healthcare
What a holder would want to know before buying AMGN: where the price sits in its own history, how far it has fallen before and whether it recovered, and what the business behind it earns. All of it is arithmetic over free market data — no opinions, no recommendations.
Today’s price is 43% above the lowest point of the past year and 7% below the highest.
Over the past year it was cheaper than today on 91% of days and more expensive on 9%. Over the last 10 years: cheaper on 99% of days.
13% above its average price of the last 200 trading days.
Fell 20% or more 6 times in 10 years. The deepest fall was 27%; the longest took 2.3 years to get back to its peak. Every one recovered.
Now 7% below the Sep 2026 peak.
Amgen Inc. · Healthcare · Drug Manufacturers - General · a mega-cap worth $224.29B
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic…
revenue profit
Sales of $36.75B in 2025, with $7.71B of profit. Sales grew in 3 of the last 3 years.
Keeps about 23 cents of every dollar of sales as profit.
Would need about 6.6 years of free cash flow to repay all its debt.
You pay $26 for every $1 of last year’s profit, and $17 for every $1 of profit expected next year.
A high number means buyers expect growth; a low one means they expect little, or fear trouble. Large US companies have averaged roughly 15–20 over the decades.
Pays 2.47% a year in dividends at today’s price · next ex-dividend Aug 21.
34 analysts: 12 say buy, 17 hold, 5 sell. Their average 12-month target is $395.25 (range $225.00–$500.00).
Insiders made 0 purchases and 4 sales in the last 6 months. Executives routinely sell shares they were paid in; buying with their own money is the rarer signal.
Free data from Yahoo Finance, refreshed daily. This is evidence about the business and its price history, not a recommendation.
Poshkan is paper trading: real prices, virtual money. Buy AMGN with $10,000 that isn’t real, set a stop before you enter, and find out what your idea would actually have done.
Data from Yahoo Finance, refreshed hourly. Nothing here is financial advice. Poshkan is a paper-trading simulator — all money, trades and returns are virtual.